ADCT | ADC Therapeutics (NYSE:ADCT) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of ADC Therapeutics (NYSE:ADCT) from a sell rating to a hold rating in a research note released on Tuesday morning, reports.According to Zacks, “ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company.It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological […]Daily Political